22. October 2020

New Zedira blog published about novel oral FXIIIa blockers

Zedira Logo                                                                                                                                                                          Transglutaminase-Newsletter | September 2020

Dear Transglutaminase researchers,

In our current blog Martin Stieler (Zedira’s head of structural biology) provides his perspective on an intriguing question: Can we design an oral FXIIIa blocker? Or is this going to be a “mission impossible”?

Blood coagulation factor XIII is considered being a qualified target for the development of safer anticoagulants. ZED3197 is the first drug-like compound addressing FXIIIa. Its physicochemical features predispose the compound for i.v. application in the acute care setting.

What about a new drug discovery program to design an oral compound? Curious? Then follow the link to learn more about Zedira’s concept for novel oral FXIIIa blockers.

Further, we would like to inform you about our top FXIII products for your research!


Art. No. Name Unit Price


Human blood coagulation Factor XIII-A2, recombinant
(hFXIII, A subunit, recombinantly produced in insect cells)

200 µg 370 €

Human Factor XIIIa, Thrombin activated
(hFXIIIa, recombinantly produced in insect cells)

200 µg 520 €

Human blood coagulation Factor XIII B subunit
(hFXIII B, F13B, recombinantly produced in insect cells)

200 µg 370 €

Assays and Substrates

Art. No. Name Unit Price


FXIII-Assay Substance,

10 mg
520 €

FXIII-Assay Kit
(ready to use, contains A101 and thrombin)

1 Kit
575 €

Blood coagulation FXIII-substrate-peptide F11KA

10 mg
310 €


Art. No. Name Unit Price


1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride

10 mg
480 €

(Synonym ZED1301, site specific irreversible inhibitor of FXIII)

5 mg
480 €


Art. No. Name Unit Price


Polyclonal antibody to human factor XIII (A-subunit)

500 µg
365 €

FITC-labeled polyclonal antibody to human factor XIII (A-subunit)

200 µg
395 €
A154 Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09)

200 µg 365 €

Monoclonal antibody against crosslinked fibrin ("D-dimer")

100 µg
365 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA